Pancreatic cancer
Conditions
Interventions
Experimental group:Steep pulse (nanoknife) ablation
Sponsors
The First Medical Center of Chinese PLA General Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Patients aged between 18 and 80 years old with no gender limitation; 2. Patients with pancreatic malignancy with pathologically confirmed clinical AJCC stage (8th edition) T4NOMO in stage ? and ? (no more than 3 localized lymph node metastases), both newly treated and retreated patients were acceptable; 3. Tumor size (measured by the maximum transverse diameter of preoperative enhanced MRI scan) 50; 6. The subject voluntarily signs the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with severe arrhythmias, a history of epilepsy or pacemaker implantation, and patients with recent large-scale myocardial infarction; 2. Patients with severe cardiac, pulmonary or renal insufficiency or who cannot tolerate endotracheal intubation under general anesthesia; 3. Those who are allergic to contrast agents or unable to perform MRI enhanced scanning for other reasons; 4. Patients with hemoglobin = 40 µmol /L; 8. Acute stage of acute infection or chronic infection; 9. Persons with mental abnormality or history of mental illness and unable to cooperate voluntarily; 10. Those who have taken anticoagulant drugs or abnormal coagulation function within 1 week; 11. Pregnant and lactating women and those who plan to become pregnant within one year; 12. Participants in clinical trials of any drugs and/or medical devices within 3 months prior to enrollment; 13. Any other factors that the investigator considers inappropriate for inclusion or that may affect the subjects' participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The success rate of ablation;The effective rate of ablation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rates (ORR) at 1, 3 and 6 months after ablation;Clinical benefit rate (CBR) at 6 months after tumor ablation;Time to disease control (DDC) after pancreatic tumor ablation; | — |
Countries
China
Contacts
Public ContactXiao Yueyong
The First Medical Center of Chinese PLA General Hospital
Outcome results
None listed